Practitioner´s information: Inhalation therapy with
eFlow
®
rapid
:
Inhalation Solutions & Treatment Time
Active Agent
Concentration
1)
Substance
Class
1)
eFlow
®
rapid
Details
TOR
g/min
4)
MMD
μm
4)
RF %
< 5μm
4)
Time
Min
Tobramycin
300 mg / 5 ml
Aminoglycoside
Antibiotic
Serum level is comparable to standard therapy using
the PARI LC PLUS
®
nebuliser. Serum value approx.
1 μg / ml data on file (n=9).
2)
Tested with TOBI
®
(Chiron/Novartis)
0.50
3.9
73
6-8
Colistimethate sodium
79 mg (1 Mio units) /3 ml
Polymyxine
Polypeptide Antibiotic
Colistin powder has to be dissolved carefully in 3 ml
0.9 % sodium chloride solution.
Tested with Colistin CF (Grünenthal)
0.58
3.9
69
3-4
Salbutamol
2.5 mg / 2.5 ml
Bronchodilator
Beta 2 mimetic
Comparable treatment safety: Heart rate pre and post
delivery of Salbutamol (10 min after inhalation) is
comparable to LC PLUS
®
nebuliser. Data on file (n=10).
2)
Tested with Sultanol
®
forte (Glaxo Smith Kline)
0.68
4.3
64
2-3
Ipratropiumbromide
500 μg / 2 ml
Bronchodilator
Anticholinergic
Tested with Atrovent
®
(Boehringer Ingelheim)
0.69
4.3
63
1-2
Dornase alfa
2.5 mg / 2.5 ml
Mucolytic agent
Enzymatic activity remains largely stable
after nebulization (90%) as for PARI LC PLUS
®
nebuliser
2)3)
. Tested with Pulmozyme
®
(Roche)
0.61
3.9
72
2-3
Acetylcysteine
300 mg / 3 ml
Mucolytic
Tested with Fluimucil
®
(Zambon)
0.60
4.1
70
4-5
Medical product:
Isotonic sodium chloride
solution (0.9 % ) 2.5 ml
PARI NaCl Inhalation Solution
Secretolytic
Individual treatment schedule.
Tested with PARI NaCl Inhalation Solution
0.70
4.3
67
2-3
Dispensed hypertonic
saline solution
(Sodium chloride 5.8%) 2.5 ml
Secretolytic
Individual treatment schedule.
Tested with dispensed saline solution 5.8 %
0.69
4.2
69
2-3
1)
These agents are approved for inhalation therapy in Germany.
2)
Seemann et al: Improving aerosol drug delivery in CF therapy. European Cystic Fibrosis Society, 28 th European Cystic Fibrosis
Conference, Crete, Greece, June 22-25, 2005.
3)
Lichtinghagen (2004 and 2005), MHH.
4)
PARI internal tests, measured with the
Malvern MasterSizer X at 23°C and 50% relative humidity. Inspiratory flow 20 l/min. TOR, MMD, RF, time (mean values).
eFlow rapid Arzneimittelkarte für Ärzte EN 20.09.2006 14:05 Uhr Seite 2
